Cerenome Inc. (CNSY) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for CNSY, including 1 press release or news item, 1 leadership change and 1 earnings update. The most recent was published Nov 12, 2026.
Financial highlights
Full financials- Revenue, TTM
- $4.20M
- Revenue growth
- -21.0%
- Net income, TTM
- -$26.09M
- Net margin
- -620.7%
- Free cash flow, TTM
- -$23.55M
- Cash
- $2.37M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks4+100%
2026-05-172026-11-08
Mix490d
- Other1(25%)
- Leadership1(25%)
- Earnings1(25%)
- Insider1(25%)
Activity · 52 weeks43 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
4 items- INSIDERChief Business Officer Andrews Ronald Asbury was granted 92,858 stock options (SEC Form 4)4 - CERENOME, INC. (0001095981) (Issuer)
- PRCerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today announced it will host a conference call on Monday, November 16, 2026, at 8:30 a.m. Eastern Time to review REYOBIQ ReSPECT-LM clinical data scheduled for presentation at SNO on November 13 and provide a CNSide® commercial update. The Company will also report its third quarter 2026 financial results that day. Webcast and Conference CallDate/Time:Monday, November 16, 2026, at 8:30 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=vTAb1pUsDial-in:U.S.: 833-862-0853 Inter
- PRCerenome Appoints Director Ron Andrews as Chief Business OfficerHOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today announced the appointment of Ron "Ronnie" Andrews as Chief Business Officer, a newly created position. Mr. Andrews will continue to serve on the Company’s Board of Directors. In his new role, Mr. Andrews will focus on advancing Cerenome’s business development and commercial strategy, with an emphasis on expanding adoption of the CNSide® Diagnostics platform and developing strategic partnerships. He brings more than 35 years of diagnostics industry leadership experience, helping companies rais
- PRCerenome Secures National In-Network Agreement with Aetna for CNSide®Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives First national CNSide payer agreement to include both tumor cell enumeration and molecular profiling HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), announced today that it has entered into a national in-network laboratory ancillary provider agreement with Aetna Health Plans, Inc. ("Aetna"), effective November 1, 2026. The agreement establishes contracted reimbursement for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test as well
CNSY FAQ
9 questionsWhat does Cerenome Inc. do?
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric...What is the latest news on CNSY?
In the last 30 days Quantisnow tracked 4 wire items for CNSY: 1 press release or news item, 1 leadership change, 1 earnings update and 1 insider trade. The most recent was published on November 12, 2026.What is CNSY revenue?
Cerenome Inc. (CNSY) reported $4.20M of revenue for the twelve months ended Jun 30, 2026. That is down 21.0% from the year before. Revenue for fiscal 2025 was $5.21M.Is CNSY profitable?
No. Cerenome Inc. reported a net loss of $26.09M for the twelve months ended Jun 30, 2026.How much cash and debt does CNSY have?
Cerenome Inc. reported $2.37M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does CNSY stock trade?
Cerenome Inc. (CNSY) is listed on NASDAQ.What sector and industry is CNSY in?
Cerenome Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What companies are similar to CNSY?
Notable peers in the same industry include MMM (3M Company), DXCM (DexCom Inc.), SYK (Stryker Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare CNSY side-by-side with any of them on Quantisnow.How can I track CNSY on Quantisnow?
Quantisnow aggregates Cerenome Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CNSY to receive live email and push alerts on every new disclosure.